Evidence map›Paper›PMID 38321292›Full record

ReviewNature reviews. Microbiology2024

Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa.

Philip J Rosenthal, Victor Asua, Melissa D Conrad

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 97 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 4 pooled it
68.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 4 syntheses or guidelines pooled it, 126 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. A Systematic Review of Alternative Artemisinin Production Strategies.International journal of molecular sciences · 2025
    Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Review
  10. Article
  11. Bicyclononane-2,8-bis(trifluoromethyl)quinoline hybrids: synthesis, antiplasmodial and antitrypanosomal activity.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Article
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Unpacking boxes: identification of novel inhibitors of malaria parasite invasion.International journal for parasitology. Drugs and drug resistance · 2026
    Article
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 3 countries.

Philip J RosenthalUniversity of California, San Francisco, CA, USA. philip.rosenthal@ucsf.edu.ORCID http://orcid.org/0000-0002-7953-7622
Victor AsuaInfectious Diseases Research Collaboration, Kampala, Uganda.ORCID http://orcid.org/0000-0002-0489-4692
Melissa D ConradUniversity of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-9984-8030
University of California, San Francisco · USInfectious Diseases Research Collaboration · UG

Funding

Resistance of Malaria Parasites to Artemisinin-Based TherapiesR01AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2009 to 2024
$8.4M
NIAID NIH HHS R01 AI075045
6 · The paper itself

Abstract

Malaria, mostly due to Plasmodium falciparum infection in Africa, remains one of the most important infectious diseases in the world. Standard treatment for uncomplicated P. falciparum malaria is artemisinin-based combination therapy (ACT), which includes a rapid-acting artemisinin derivative plus a longer-acting partner drug, and standard therapy for severe P. falciparum malaria is intravenous artesunate. The efficacy of artemisinins and ACT has been threatened by the emergence of artemisinin partial resistance in Southeast Asia, mediated principally by mutations in the P. falciparum Kelch 13 (K13) protein. High ACT treatment failure rates have occurred when resistance to partner drugs is also seen. Recently, artemisinin partial resistance has emerged in Rwanda, Uganda and the Horn of Africa, with independent emergences of different K13 mutants in each region. In this Review, we summarize our current knowledge of artemisinin partial resistance and focus on the emergence of resistance in Africa, including its epidemiology, transmission dynamics and mechanisms. At present, the clinical impact of emerging resistance in Africa is unclear and most available evidence suggests that the efficacies of leading ACTs remain excellent, but there is an urgent need to better appreciate the extent of the problem and its consequences for the treatment and control of malaria.

Indexed as

AntimalarialsArtemisininsDrug ResistanceMalaria, FalciparumPlasmodium falciparumAfricaHumansMutationProtozoan ProteinsAntimalarialsartemisininArtemisininsProtozoan Proteins

Identifiers

PMID38321292
OpenAlexW4391565922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.